Infinimmune treats human disease with Complete Human® antibody therapeutics. The company's Anthrobody® platform enables the identification and advancement of truly human monoclonal, single-domain, and multi-specific antibodies with unparalleled efficiency, often identifying therapeutic candidates in under 3 months. Infinimmune has also developed GLIMPSE™, a powerful antibody language model for antibody engineering trained on our proprietary data.

Infinimmune’s therapeutic pipeline targets autoimmune and inflammatory diseases with a focus on first- and best-in-class opportunities. Our IFX-101 (anti-IL-22) mAb program is in cell line development at our CDMO partner, KBI Biopharma, and is slated for FIH studies in January of 2027. Our IFX-201 (anti-IL-13) mAb program is at development candidate (DC)stage and will be transferred to KBI Biopharma in January 2026. We have a robust pipeline of programs targeting high-value targets across a broad range of autoimmune conditions.